Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03971474
Title Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Southwest Oncology Group
Indications

lung non-small cell carcinoma

Therapies

Docetaxel + Gemcitabine + Pemetrexed Disodium

Docetaxel + Ramucirumab

Docetaxel + Gemcitabine

Pembrolizumab + Ramucirumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.